Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory ....Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.Read moreRead less
Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflamm ....Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflammatory disease trials. Importantly, Cpn10 appears to be anti-inflammatory rather than immunosuppressive; a critical advantage over many current anti-inflammatory interventions. Immunosuppression can lead to increased infections, which can have serious consequences, especially in elderly patients.Read moreRead less
Molecular and immunological approaches to managing Australia's seafood allergy epidemic. Seafood is an increasingly important cause of food allergy. Novel insight into the functions of why and how proteins from seafood develop to potent allergens will lead to the development of better diagnostics and therapeutics. This will assist patients to better manage their serious food allergy.